Wuhan YZY Biopharma Co (HKSE:02496) EV-to-EBIT : (As of Jun. 05, 2024)

View and export this data going back to 2023. Start your Free Trial

What is Wuhan YZY Biopharma Co EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Wuhan YZY Biopharma Co's Enterprise Value is HK$1,327.09 Mil. Wuhan YZY Biopharma Co does not have enough years/quarters to calculate its EBIT for the trailing twelve months (TTM) ended in Dec. 2023. Therefore, GuruFocus does not calculate Wuhan YZY Biopharma Co's EV-to-EBIT at this moment.

The historical rank and industry rank for Wuhan YZY Biopharma Co's EV-to-EBIT or its related term are showing as below:

HKSE:02496' s EV-to-EBIT Range Over the Past 10 Years
Min: -10.81 Med: 0 Max: 0
Current: -6.41

HKSE:02496's EV-to-EBIT is ranked worse than
100% of 425 companies
in the Biotechnology industry
Industry Median: 9.61 vs HKSE:02496: -6.41

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Wuhan YZY Biopharma Co's Enterprise Value for the quarter that ended in Dec. 2023 was HK$1,608.69 Mil. Wuhan YZY Biopharma Co does not have enough years/quarters to calculate its EBIT for the trailing twelve months (TTM) ended in Dec. 2023. Therefore, GuruFocus does not calculate Wuhan YZY Biopharma Co's Earnings Yield (Joel Greenblatt) % at this moment.

Wuhan YZY Biopharma Co EV-to-EBIT Historical Data

The historical data trend for Wuhan YZY Biopharma Co's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Wuhan YZY Biopharma Co EV-to-EBIT Chart

Wuhan YZY Biopharma Co Annual Data

Trend

Dec21

Dec22

Dec23

EV-to-EBIT

-7.77

Wuhan YZY Biopharma Co Semi-Annual Data
	Dec21	Dec22	Dec23
EV-to-EBIT	-	-	-7.77

Competitive Comparison of Wuhan YZY Biopharma Co's EV-to-EBIT

For the Biotechnology subindustry, Wuhan YZY Biopharma Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Wuhan YZY Biopharma Co's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Wuhan YZY Biopharma Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Wuhan YZY Biopharma Co's EV-to-EBIT falls into.

Wuhan YZY Biopharma Co EV-to-EBIT Calculation

Wuhan YZY Biopharma Co's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	1327.088	/
	=

Wuhan YZY Biopharma Co (HKSE:02496) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Wuhan YZY Biopharma Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 )	=	EBIT	/	Enterprise Value (Q: Dec. 2023 )
	=		/	1608.6921
	=	%

Wuhan YZY Biopharma Co EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Wuhan YZY Biopharma Co's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Wuhan YZY Biopharma Co (HKSE:02496) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Wuhan YZY Biopharma Co Ltd (HKSE:02496) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 666 Gaoxin Road, East Lake High Tech, Development Zone, Hubei Province, Wuhan, CHN

Website

https://en.yzybio.com/

Wuhan YZY Biopharma Co Ltd is a biotechnology company specifically involved in developing bispecific antibody based therapies to treat cancer or cancer-associated complications, cancer and age-related ophthalmologic diseases to address medical demands in oncology and aging-related ophthalmologic disease areas, The Company has been operating in one reportable segment, being the discovering, developing and commercializing new class of innovative medicines in respect to anti-tumor bispecific antibody.

Executives

Dragon Merit Holdings Limited	2201 Interest of corporation controlled by you
Robust Sun Holdings Limited	2201 Interest of corporation controlled by you
Cspc Pharmaceutical Group Limited	2201 Interest of corporation controlled by you
Shi Yao Ji Tuan En Bi Pu Yao Ye You Xian Gong Si	2101 Beneficial owner
He Bei Yi Er Qi Ye Guan Li Zi Xun You Xian Gong Si	2201 Interest of corporation controlled by you
Ning Bo Mei Shan Bao Shui Gang Qu Guang Rui Hong Xiang Gu Quan Tou Zi He Huo Qi Ye You Xian He Huo	2101 Beneficial owner
Guo Xin Si Chuang Tou Zi Ji Jin Guan Li Bei Jing You Xian Gong Si	2201 Interest of corporation controlled by you
Guo Hong Wei
Nan Jing Cai Zhi Er Hao Qi Ye Guan Li He Huo Qi Ye You Xian He Huo	2101 Beneficial owner
Nan Ning Hui You Xing Yao Gu Quan Tou Zi Ji Jin He Huo Qi Ye You Xian He Huo
Nan Ning Yao You Shang Wu Zi Xun He Huo Qi Ye You Xian He Huo
Wen Zhi Cheng
Tong De Qian Yuan Bei Jing Tou Zi Guan Li You Xian Gong Si
Wang Hongjie	2201 Interest of corporation controlled by you
Wu Shangzhi	2201 Interest of corporation controlled by you

Wuhan YZY Biopharma Co (HKSE:02496) Headlines

No Headlines